Seres Therapeutics (MCRB) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

MCRB Seres Therapeutics

Watchlist

0.850
-0.020-2.30%

Close Jan 8 16:00 ET

0.942
+0.092+10.81%

Pre 05:13 ET

145.13MMarket Cap-4.05P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended
MT Newswires12:33 ET
Express News | Seres Therapeutics Inc - Ser-155 Shows 77% Relative Risk Reduction in Bloodstream Infections
ReutersJan 9 07:01 ET
Express News | Seres Therapeutics Inc - Ser-155 Shows Significant Decrease in Fecal Albumin and Systemic Inflammation
ReutersJan 9 07:01 ET
Express News | Seres Therapeutics Inc - Extends Cash Runway Into Q1 2026
ReutersJan 9 07:00 ET
Express News | Seres Therapeutics Announces New Translational Biomarker Results From Ser-155 Phase 1B Clinical Study and Provides Corporate Updates
ReutersJan 9 07:00 ET
Seres Therapeutics Announces New Translational Biomarker Results From SER-155 Phase 1b Clinical Study and Provides Corporate Updates
GlobeNewswireJan 9 07:00 ET

Comments

Teddy123

7 hours ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

$Seres Therapeutics (MCRB.US)$
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows

Jaguar8

21 hours ago

NEWS

$Seres Therapeutics (MCRB.US)$
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
Thursday, 9th January at 7:00 am
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres' live ...

flabbyduck

Dec 9, 2024 06:24

$Seres Therapeutics (MCRB.US)$ may this fly later. (:

Trytosaveabit

Dec 9, 2024 06:04

News

$Seres Therapeutics (MCRB.US)$ Reuters· 3 mins ago
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)

Jaguar8

Dec 9, 2024 06:03

NEWS

$Seres Therapeutics (MCRB.US)$
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Ser...

Heat List

Overall

No Data